Theriva Biologics, INC 8-K filings

Theriva Biologics reports positive topline outcomes from its VIRAGE Phase 2b clinical trial, showing improved survival rates for patients with metastatic pancreatic cancer treated with VCN-01 plus standard chemotherapy.

Theriva Biologics reports positive safety outcomes from the second IDMC review of its VIRAGE Phase 2b clinical trial, indicating VCN-01 is well-tolerated in combination with chemotherapy for metastatic pancreatic cancer.

Theriva Biologics reports full-year 2024 financial results, highlighting clinical and regulatory achievements and providing a corporate update on its key programs.

Theriva Biologics announced positive feedback from the FDA regarding the design of a Phase 3 clinical trial for their lead candidate VCN-01 in combination with chemotherapy for metastatic pancreatic cancer.

Theriva Biologics reported its third quarter 2024 financial results, highlighted by the completion of patient enrollment in a key pancreatic cancer trial and progress in other clinical programs.

Theriva Biologics has increased its authorized shares and amended its stock incentive plan following its 2024 Annual Meeting of Stockholders.

Theriva Biologics has been granted orphan medicinal product designation by the European Commission for its lead clinical candidate VCN-01, aimed at treating retinoblastoma.

Theriva Biologics' Phase 1b/2a clinical trial of SYN-004 for preventing acute graft-versus-host-disease has received a positive review from the Data and Safety Monitoring Committee, allowing the study to proceed to the next cohort.

Theriva Biologics has announced the pricing of a public offering expected to generate approximately $2.5 million in gross proceeds.

Theriva Biologics has successfully enrolled all 92 targeted patients in its VIRAGE Phase 2b clinical trial for metastatic pancreatic cancer.

Theriva Biologics has been awarded $2.28 million in funding from the Spanish government to advance its THERICEL project, a suspension cell platform for manufacturing viral-based therapies.

Theriva Biologics converted 4,138 shares of Series C and 100,000 shares of Series D preferred stock into 27,316 shares of common stock, eliminating all outstanding shares of these preferred series.

Theriva Biologics has completed a 1-for-25 reverse stock split to comply with NYSE American listing standards, effective August 26, 2024.

Theriva Biologics has announced a 1-for-25 reverse stock split to meet the per share price requirements of the NYSE American.

Theriva Biologics reported its second quarter 2024 financial results and provided an update on its clinical programs, including the expected completion of enrollment for its Phase 2b trial in metastatic pancreatic cancer.

Theriva Biologics has been granted Rare Pediatric Drug Designation by the FDA for its lead product candidate, VCN-01, for the treatment of retinoblastoma.

Theriva Biologics has been granted Fast Track Designation by the FDA for its lead candidate VCN-01 in combination with chemotherapy for the treatment of metastatic pancreatic cancer.

Theriva Biologics has received notice of conversion of 135,431 shares of Series C Convertible Preferred Stock into 888,072 shares of common stock at a price of $1.22 per share.

Theriva Biologics announced positive topline data from a Phase 1 trial for retinoblastoma and provided a corporate update including financial results for the first quarter of 2024.

Theriva Biologics has amended its sales agreement with A.G.P./Alliance Global Partners to update its at-the-market offering and terminated its agreement with B. Riley Securities.

Theriva Biologics reports positive topline data from a Phase 1 trial of VCN-01 in pediatric retinoblastoma, leading to an exclusive worldwide license.

Theriva Biologics reports preclinical data showing enhanced anti-tumor effects when combining their lead product candidate, VCN-01, with liposomal irinotecan in pancreatic cancer models.

Theriva Biologics is advancing its oncolytic virus platform with a focus on VCN-01 and the Albumin Shield technology, targeting multiple cancer indications.

Theriva Biologics announced its full-year 2023 financial results and provided an update on its clinical programs, highlighting the progress of its VIRAGE trial and a cash runway into the first quarter of 2025.

The Independent Data Monitoring Committee has recommended the continuation of Theriva Biologics' Phase 2b VIRAGE trial for VCN-01 in combination with chemotherapy for metastatic pancreatic cancer, with no safety concerns raised.